Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-26

FDA Approved: TEZSPIRE — Supplemental Application (Amgen Inc)

View source ↗

Summary

FDA approved a supplemental application for Tezspire (tezepelumab-ekko) from Amgen, updating the product label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tezspire (tezepelumab)

Snippet

SUPPL AP for TEZSPIRE (TEZEPELUMAB-EKKO)